Repaglinide
- Generic Name
- Repaglinide
- Brand Names
- Enyglid, Gluconorm, Prandin, NovoNorm, Repaglinide Krka, Repaglinide Accord, Repaglinide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O4
- CAS Number
- 135062-02-1
- Unique Ingredient Identifier
- 668Z8C33LU
- Background
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood ...
- Indication
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
- Conditions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 187
- Registration Number
- NCT00491725
Effect of GlucoNorm vs Glyburide on Post-Prandial Hyperglycemia in Elderly Subjects With Type 2 Diabetes
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 30
- Registration Number
- NCT00451620
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
- Conditions
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2006-06-13
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00336310
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan
Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 100
- Registration Number
- NCT00118950
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 102
- Registration Number
- NCT00118963
- Locations
- 🇩🇰
Steno Diabetes Center, Gentofte, Denmark
Diabetes Therapy to Improve BMI and Lung Function in CF
- Conditions
- Interventions
- First Posted Date
- 2003-11-14
- Last Posted Date
- 2012-02-28
- Target Recruit Count
- 108
- Registration Number
- NCT00072904
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.